Article

Engineered Red Blood Cells Carrying PCSK9 Inhibitors Persistently Lower LDL and Prevent Obesity

2020-11-02

Abstract excerpt

Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR), very low-density lipoprotein receptors (VLDLR), apolipoprotein E receptor 2 (ApoER2), and lipoprotein receptor–related protein 1 (LRP...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cc56cc97-8048-582d-a450-137fdd19993f
DOI: 10.1101/2020.11.02.364620

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Engineered Red Blood Cells Carrying PCSK9 Inhibitors Persistently Lower LDL and Prevent ObesityDOI 10.1101/2020.11.02.364620Read

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read

New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.Semantic proximity Read

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.Semantic proximity Read

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− miceSemantic proximity Read